Beiersdorf Aktiengesellschaft
Explore by topic
5-year stock timeline
May 2021
Vincent Warnery appointed Chief Executive Officer effective 1 May 2021, following Stefan De Loecker's departure and an Executive Board reshuffle. The market interpreted the leadership transition as continuity paired with sharper strategic focus around C.A.R.E.+ (sustainability, innovation, digitalisation, growth). The business was exiting the worst pandemic effects, and the stock entered a recovery-phase uptrend. [12], [14], [24], [21], [1]
FY 2021 (reported Mar 1, 2022)
Group sales reached €7,627m with organic growth of 9.7%; Consumer sales €6,129m (organic +8.8%). The company reported progress on C.A.R.E.+ initiatives and EBIT excluding special factors around 13.0%. Investor perception shifted from pandemic recovery to operational stability — Beiersdorf began to be viewed as a low-single to mid-single-digit organic growth compounder. The stock rallied on confirmatory fundamentals. [1], [3], [11], [21]
2022 — broad-based acceleration
Strong, broad-based growth throughout 2022 pushed group sales toward €8.8bn. Management repeatedly reported double-digit organic growth trends and raised visibility. The market increasingly regarded Beiersdorf as a growth story again, with outperformance in Consumer and strong tesa contribution. The stock broke out and sustained an uptrend as investors rewarded accelerating top-line and margin stability. [13], [18], [25], [32]
FY 2023 (reported Feb 29, 2024)
Record Group sales of €9.5bn (organic +10.8%); Consumer €7.8bn (organic +12.5%); NIVEA exceeded €5bn (NIVEA +16.2%); Derma grew 24%. The board proposed a dividend increase to €1.00 and approved a share buyback program up to €500m. The market framed Beiersdorf as the fastest-growing beauty company in its peer group, with narrative shifting to growth plus direct shareholder returns. The stock rallied on strong results and capital-return plans. [31], [35], [36]
FY 2024 (reported Feb 25, 2025)
Record FY2024 sales of €9,850m (organic +6.5%); EBIT excluding special factors €1,370m (EBIT margin 13.9%); the company continued significant investments. Year-end share price closed at €124.00. Execution and margin progress reinforced the quality-compounder story, but investors began taking profits after a multi-year run. The stock entered a plateau and consolidation phase. [28], [32], [36]
Q1–H1 2025 (Apr–Aug 2025)
Q1 2025: Group organic growth +3.6% (nominal +3.3%); Derma and tesa strongly outperformed, while La Prairie posted a steep Q1 decline of -17.5%. The Board approved another buyback program (up to €500m) in February 2025. H1 2025: Group sales €5.2bn (organic +2.1%); EBIT excluding special factors €836m (EBIT margin 16.1%). The company trimmed FY 2025 Consumer sales guidance to 3–4% (from 4–6%) and reduced expected margin uplift. Market tone shifted to caution as slowing end-markets, China repositioning and travel-retail destocking raised doubts about near-term growth despite Derma strength and buybacks. The stock entered a corrective phase with rising volatility. [37], [38], [39], [41]
FY 2025 (reported Mar 2, 2026)
Full-year 2025: Group sales €9.9bn, organic growth +2.4%. Derma again outperformed, but overall group growth materially decelerated versus 2023–24. Investors re-priced the stock toward a more mature, cyclical profile with emphasis on margin management, buybacks and Derma resilience while luxury and travel retail remained headwinds. The stock extended its downtrend into 2026 with materially lower multiples and significant share-price retracement. [44], [41]
Key risks and downside factors
Beiersdorf straddles two distinct competitive landscapes. On the skincare side—NIVEA, Eucerin, La Prairie—it contends with global beauty and CPG heavyweights like L'Oréal, Unilever, Procter & Gamble, Kenvue and Estée Lauder, while also facing pressure from nimble DTC brands, natural product makers and regional players who move faster on pricing and innovation. Its adhesives business (tesa) competes against specialist suppliers and larger industrials like Henkel, 3M and Avery Dennison. The dual exposure creates layered risks: competitive intensity across both segments, input-cost and supply-chain volatility, geographic and currency headwinds, plus the ever-present threat of regulatory or reputational friction around product safety and ESG compliance.
- Intense competition from established global CPG and prestige-beauty players, alongside fast-growing indie and DTC brands, poses a persistent threat to market share and pricing power in both mass and premium skincare segments.
- Volatile raw-material, packaging, and energy costs pose a tangible risk to margins across both the cosmetics and tesa adhesives divisions, with potential supply-chain disruptions capable of materially elevating cost of goods sold.
- Geographic and currency exposure creates meaningful volatility, particularly where emerging market growth—China especially—drives a material portion of revenue. Softening demand or adverse FX movements can swing earnings materially.
- Regulatory, safety, and reputational risks—including ingredient bans, recalls, animal-testing or regulatory changes, ESG controversies, and data or privacy issues—can trigger fines, product withdrawals, and erosion of consumer trust.
Competitive landscape
Beiersdorf operates across mass, dermo-cosmetic and prestige segments with brands including Nivea, Eucerin, La Prairie and Tesa adhesives. It faces competition from established global FMCG and cosmetics groups alongside faster-moving DTC and niche players. The most direct public competitors are L'Oréal, Unilever, P&G, Johnson & Johnson/Kenvue, Estée Lauder, Henkel, Shiseido, Kao, Colgate-Palmolive and Reckitt, which collectively exert pricing, innovation and distribution pressure across the market. The company's material risks center on margin compression from competitive intensity and volatile input and packaging costs. International and emerging market exposure carries FX and geopolitical headwinds. Regulatory, reputational and legal risks merit attention—Beiersdorf has faced competition-related fines in its history. [Beiersdorf and competitor company pages / public filings and company summaries]
| Company | Ticker |
|---|---|
| L'Oréal S.A. | OR.PA |
| Procter & Gamble Co. | PG.NYSE |
| Johnson & Johnson | JNJ.NYSE |
| Kenvue Inc. | KVUE.NYSE |
| Estée Lauder Companies Inc. | EL.NYSE |
| Henkel AG & Co. KGaA | HEN.XETRA |
| Colgate-Palmolive Company | CL.NYSE |
Private competitors
- Glossier
- Paula's Choice
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialPerformance Figures of Beiersdorf Aktiengesellschaft
Relative Performance vs Benchmarks
| Period | Beiersdorf Aktiengesellschaft | vs DAX | vs S&P 500 (SPY) |
|---|---|---|---|
| 1M | +12.94% | +12.92% | +12.08% |
| 3M | +3.20% | +2.34% | -3.36% |
| 6M | -17.61% | -16.10% | -27.32% |
| 1Y | -24.85% | -28.62% | -47.11% |
| 3Y | -29.13% | -84.19% | -102.92% |
| 5Y | -18.27% | -78.60% | -105.51% |
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialHistorical valuation trends
How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.
| Period | P/E Ratio | P/S Ratio | P/B Ratio | P/CF Ratio |
|---|---|---|---|---|
| Current | 25.9 | 2.4 | 2.0 | 20.9 |
| 1Y ago | 14.8 | 1.2 | 2.8 | 11.7 |
| 3Y ago | 21.7 | 1.9 | 3.2 | 28.1 |
| 5Y ago | 23.6 | 2.1 | 3.5 | 12.7 |
Frequently Asked Questions
Where is the Beiersdorf Aktiengesellschaft stock traded?
What does Beiersdorf Aktiengesellschaft do?
What are the key metrics for BEI.XETRA?
How has Beiersdorf Aktiengesellschaft's stock price performed?
How is BEI.XETRA valued?
Does BEI.XETRA pay dividends?
What are the key risks when investing in BEI.XETRA?
- Intense competition from established global CPG and prestige-beauty players, alongside fast-growing indie and DTC brands, poses a persistent threat to market share and pricing power in both mass and premium skincare segments.
- Volatile raw-material, packaging, and energy costs pose a tangible risk to margins across both the cosmetics and tesa adhesives divisions, with potential supply-chain disruptions capable of materially elevating cost of goods sold.
- Geographic and currency exposure creates meaningful volatility, particularly where emerging market growth—China especially—drives a material portion of revenue. Softening demand or adverse FX movements can swing earnings materially.
- Regulatory, safety, and reputational risks—including ingredient bans, recalls, animal-testing or regulatory changes, ESG controversies, and data or privacy issues—can trigger fines, product withdrawals, and erosion of consumer trust.
Who are the main competitors of Beiersdorf Aktiengesellschaft?
- L'Oréal S.A. (OR.PA)
- Procter & Gamble Co. (PG.NYSE)
- Johnson & Johnson (JNJ.NYSE)
- Kenvue Inc. (KVUE.NYSE)
- Estée Lauder Companies Inc. (EL.NYSE)
- Henkel AG & Co. KGaA (HEN.XETRA)
- Colgate-Palmolive Company (CL.NYSE)
When does Beiersdorf Aktiengesellschaft report earnings?
Key Metrics
Valuation Metrics
Profitability Metrics
Growth Metrics
Dividend history
Long-term record of paid dividends (amount per share and dividend yield at the time of payment).
| Year | Dividend | Yield at payment | Avg. yield |
|---|---|---|---|
| 2026 | 1.00 EUR | 1.35% | 0.88% |
| 2025 | 1.00 EUR | 0.84% | |
| 2024 | 1.00 EUR | 0.74% | |
| 2023 | 0.70 EUR | 0.57% | |
| 2022 | 0.70 EUR | 0.74% | |
| 2021 | 0.70 EUR | 0.78% | |
| 2020 | 0.70 EUR | 0.74% | |
| 2019 | 0.70 EUR | 0.76% | |
| 2018 | 0.70 EUR | 0.76% | |
| 2017 | 0.70 EUR | 0.77% | |
| 2016 | 0.70 EUR | 0.88% | |
| 2015 | 0.70 EUR | 0.87% | |
| 2014 | 0.70 EUR | 0.99% | |
| 2013 | 0.70 EUR | 1.03% | |
| 2012 | 0.70 EUR | 1.33% |
Earnings history & estimates
Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.
Historical earnings performance
Upcoming earnings report
Analyst estimates for upcoming periods
Key financial figures
Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 9.85B | 9.85B | 9.45B | 8.80B | 7.63B |
| Operating income (EBIT) | 1.35B | 1.30B | 1.10B | 1.22B | 980.00M |
| Net income | 939.00M | 912.00M | 736.00M | 755.00M | 638.00M |
| Free cash flow | 373.00M | 794.00M | 424.00M | 249.00M | 580.00M |
| Total assets | 12.85B | 13.01B | 12.63B | 12.35B | 11.30B |
| Equity | 8.60B | 8.47B | 8.32B | 7.79B | 6.87B |
| Net debt | -983.00M | -941.00M | -1.03B | -722.00M | -757.00M |
PWP Leeway UG (haftungsbeschränkt)
